The NAD+ benefits list, and the intervention behind each line
It sounds pedantic. It is the difference between an accurate reference list and a misleading page, and it is the reason two people can read the same citations and come away with opposite impressions of how well supported this market is.
Read the second and third columns together and the pattern is hard to miss. The rows with human data behind them describe an oral capsule. The rows describing the product with a cannula in it are supported by mechanism, by animals, or by nobody.
| Claim you will see | What was actually given in the research | Organism | What the finding will carry |
|---|---|---|---|
| Raises cellular NAD levels | Oral precursor, nicotinamide riboside or nicotinamide mononucleotide | Humans | Blood levels rise. Replicated. The firmest thing on this table |
| Activates sirtuins and supports DNA repair | The coenzyme added directly, or precursors | Cultured cells and mice | Mechanism, not outcome |
| Slows ageing | Precursors, and genetic manipulation of the pathway | Mice, worms and yeast, with mixed results | A hypothesis worth testing in people, not a result in people |
| Improves muscle function and insulin sensitivity | Oral precursor | Humans, in trials whose results do not agree with each other | Nothing settled either way |
| Restores energy and mental clarity | Usually nothing controlled | No controlled human data for the infusion | Testimonial only |
| Eases withdrawal in addiction recovery | Infusion, in clinic practice | Humans, without controlled comparison | Practice reports, not evidence of effect |
| Reverses hangovers and jet lag | Nothing | None | Marketing |
The one human result that replicates
Give people an oral precursor and the amount of the coenzyme measurable in their blood goes up. More than one research group has shown this in humans. It is dose related, it is reasonably consistent, and anyone who dismisses this whole field as unstudied is wrong about that specific point.
That finding deserves to be stated plainly, because scepticism that flattens everything into nothing is as unhelpful as a sales page. There is a real, reproducible human pharmacology here. The argument is about what follows from it.
A biomarker that moved is not a person who improved
What follows from it, so far, is less than the market implies. Trials in humans given oral precursors have looked at physical performance, insulin sensitivity, markers of inflammation and measures of muscle function, and the results across those trials do not point the same way. Some found small changes. Some found none. That is what an unsettled question looks like when it is being investigated honestly.
The step being skipped in most marketing is the one between the blood level and the person. A biomarker is chosen because someone believes it tracks something that matters. Believing that is not the same as having shown it. Drug development is full of markers that moved beautifully while the outcome they were supposed to predict did not move at all.
So the correct sentence is narrow and dull: oral precursors raise a measurable level in humans, and whether that produces a change a person would notice is not established. A page that gives you only the first half of that sentence has not lied to you. It has finished early.
Why the energy claim is the hardest of them to test
Energy is the claim most people are actually buying, and it is close to the worst possible outcome to measure.
It has no unit. It fluctuates with sleep, illness, mood, workload and the seasons. It responds strongly to expectation, which is why placebo controlled designs exist at all. And it is being asked about in a setting engineered to produce it: an hour of enforced stillness, no phone calls, attention from a clinician, and a fee already paid that a person would rather feel was worth paying.
None of that means people are lying when they report feeling better after an infusion. Many of them genuinely do feel better. It means that a report of feeling better in that setting cannot distinguish between the contents of the bag and everything else in the room, and only a controlled comparison can. For the infusion, that comparison has not been published.
The withdrawal claim, which deserves separating from the rest
One row on that table should not be filed with hangovers, because the people it is aimed at are in a different position from someone booking a wellness drip.
Infusions are marketed to people in early recovery from alcohol or opioid dependence, sometimes as a multi day course, and the appeal is obvious. Withdrawal is miserable, the treatment options people have already tried may have failed them, and a clinic offering relief is speaking to real distress.
What exists behind that offer is practice reporting: clinicians describing what they observed in their own clients, without a comparison group and without blinding. Withdrawal symptoms also resolve on their own over days, which is precisely the situation in which an uncontrolled series will look effective no matter what was in the bag. Nobody has published the controlled human comparison that would separate the infusion from time, supportive care and attention.
The stakes are what make this row different. Someone spending a large sum on infusions instead of on a treatment with an evidence base has lost more than money, and relapse risk is not a theoretical harm. If a provider offers this, the question to put to them is direct: what controlled evidence exists for this use, in people, with the infusion rather than a precursor, and if there is none, say so.
Where the ageing claims come from, species by species
The ageing story is the engine of the whole category, and it comes from a real and interesting body of laboratory work.
In yeast, worms and mice, manipulating this pathway, sometimes by feeding precursors, sometimes genetically, has changed measures of lifespan or of function in later life. Some of those results have been influential. Others have been contested or have failed to reproduce cleanly, which is normal for ageing research and is rarely mentioned on a clinic page.
Two problems block the jump from there to a person in a chair. The first is species. Mice differ from humans in how they handle this pathway, and mouse lifespan work has an unhappy record of not transferring. The second is intervention. Most of the animal work fed a precursor. It did not put the finished coenzyme into a vein.
The animal work is a reason to run human trials. It is not a human result, and describing it as one requires dropping the organism from the sentence.
What an hour in the chair is being measured against
A benefits list only means something next to an alternative, and the alternative here is unusually cheap.
If the mechanism the market believes in is real, an oral precursor is the intervention with the human pharmacology behind it, it costs a fraction of an infusion, it needs no clinic, and it carries no cannula. A page selling the infusion has to explain why the more expensive and more invasive route is better, and the honest answer is that nobody has shown that it is. Whether the injected coenzyme even enters cells intact is still argued over by researchers.
There is also the alternative nobody prints: the causes of low energy that a metabolic panel, a sleep assessment or a conversation about workload would find. An infusion booked for tiredness is, among other things, an hour spent not investigating why you are tired.